Pulmonary arterial hypertension (PAH) is characterized by vascular obstruction and variable presence of vasoconstriction, leading to increased pulmonary vascular resistance and right ventricular failure. Despite its profound clinical consequences with high morbidity and mortality, therapeutic advances over the past 20 years have modestly improved survival of PAH patients. The combined use of available drugs to maximize the clinical benefit is an emerging strategy for the treatment of PAH. Pulmonary vascular endothelial nitric oxide (NO) synthase (eNOS)- derived NO is the major stimulant of cyclic guanosine 5'monophosphate (cGMP) production and NO/cGMP-dependent vasorelaxation in the pulmonary circulation. Alternatively, pulmonary vascular cGMP levels can also be elevated via inhibition of phosphodiesterase type 5 (PDE5) to achieve a similar response. We recently reported that an eleven amino acid (SSWRRKRKESS) synthetic peptide (P1) stimulates the catalytic activity of eNOS and causes NO/cGMP-dependent sustained vasorelaxation in isolated pulmonary artery (PA) segments and in lung perfusion models. More recent preliminary data suggest that P1 stimulation increases intracellular NO release and inhibits cGMP-specific PDE5 in pulmonary artery endothelial cells. Based on our earlier report and preliminary studies we hypothesize that P1 treatment with its unique dual action as a NO-releasing PDE5 inhibitor can be used as a novel therapeutic approach for the treatment of PAH. To test this hypothesis, the present study is designed to: 1) develop a physiologically relevant preclinical animal model of PAH with specific focus on assessment of bioavailability, dosing regimen, and efficacy of P1 therapy on the hemodynamic, histologic, and biochemical changes, and 2) identify the specific molecular events associated with P1-mediated caveolin-1/eNOS dissociation and activation of eNOS as well as the effects of P1 on PDE5 activity and cGMP hydrolysis. We anticipate that confirmation of mechanism-based dual action of this novel therapeutic peptide in a preclinical animal model will facilitate Phase I clinical trials for P1 treatment of PAH.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL085133-04
Application #
7993570
Study Section
Lung Injury, Repair, and Remodeling Study Section (LIRR)
Program Officer
Colombini-Hatch, Sandra
Project Start
2007-12-01
Project End
2013-11-30
Budget Start
2010-12-01
Budget End
2013-11-30
Support Year
4
Fiscal Year
2011
Total Cost
$315,000
Indirect Cost
Name
University of Florida
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Hutchinson, Tarun E; Hu, Hanbo; Patel, Jawaharlal M (2016) Cell Penetrating Peptide-Mediated Caveolae-Dependent Activation of Lung Endothelial Nitric Oxide Synthase. Protein Pept Lett 23:169-75
Hutchinson, Tarun E; Patel, Jawaharlal M (2015) Peptide-stimulated angiogenesis: Role of lung endothelial caveolar signaling and nitric oxide. Nitric Oxide 51:43-51
Hutchinson, Tarun E; Zhang, Jianliang; Xia, Shen-Ling et al. (2012) Enhanced phosphorylation of caveolar PKC-α limits peptide internalization in lung endothelial cells. Mol Cell Biochem 360:309-20
Hu, Hanbo; Zharikov, Sergey; Patel, Jawaharlal M (2012) Novel peptide for attenuation of hypoxia-induced pulmonary hypertension via modulation of nitric oxide release and phosphodiesterase -5 activity. Peptides 35:78-85
Zhang, Jianliang; Hu, Hanbo; Palma, Nadia L et al. (2012) Hypoxia-induced endothelial CX3CL1 triggers lung smooth muscle cell phenotypic switching and proliferative expansion. Am J Physiol Lung Cell Mol Physiol 303:L912-22
Krotova, Karina; Patel, Jawaharlal M; Block, Edward R et al. (2010) Hypoxic upregulation of arginase II in human lung endothelial cells. Am J Physiol Cell Physiol 299:C1541-8
Zharikov, Sergey I; Swenson, Erik R; Lanaspa, Miguel et al. (2010) Could uric acid be a modifiable risk factor in subjects with pulmonary hypertension? Med Hypotheses 74:1069-74
Krotova, Karina; Patel, Jawaharlal M; Block, Edward R et al. (2010) Endothelial arginase II responds to pharmacological inhibition by elevation in protein level. Mol Cell Biochem 343:211-6
Hutchinson, Tarun E; Kuchibhotla, Sudeep; Block, Edward R et al. (2009) Peptide-stimulation enhances compartmentalization and the catalytic activity of lung endothelial NOS. Cell Physiol Biochem 24:471-82